PPAR Research

PPARs, RXRs, and Drug-Metabolizing Enzymes


Publishing date
01 Nov 2009
Status
Published
Submission deadline
01 May 2009

Guest Editors

1Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272-0095, USA


PPARs, RXRs, and Drug-Metabolizing Enzymes

Description

Numerous studies have implicated PPAR/RXR activation of drug metabolizing enzymes in both drug efficacy and drug-induced idiosyncrasies. Studies suggest that modulation of PPARa, PPARd, and PPAR? induction of drug-metabolizing enzymes, especially cytochrome P450, results in altered pharmacokinetics and/or pharmacodynamics impacting drug therapeutic efficacy and/or adverse drug reactions.

A more comprehensive understanding of how different PPARs and RXRs interact to regulate the phase I, phase II, and phase III enzymes may provide significant insight into the rational choice of drug combinations that offer the best therapeutic outcome.

The purpose of this special issue of PPAR Research is to give authors an opportunity to present original research articles and reviews addressing all aspects of PPAR biology related to drug metabolism, drug efficacy, adverse drug reaction, and the biology, pharmacology, and therapeutic use of PPAR and RXR agonists. Potential topics include (but are not limited to):

  • Regulation of phase I drug-metabolizing enzymes by PPAR and RXR agonists
  • Novel agonists and antagonists of PPAR and RXR function in the drug metabolism
  • Control of phase II conjugating enzymes in drug metabolism
  • Exploring drug metabolism with humanized and PPAR knockout mice
  • Regulation of cholesterol and bile acid metabolism by PPAR and RXR agonists
  • Phase III ABC drug transporter regulation by PPAR
  • Metabolomics: metabolic profiling of PPAR and RXR agonists
  • PPAR agonist and antagonist in human and rodent chemically induced toxicity
  • Control of ethanol metabolism by PPARs and RXRs in alcoholic liver disease
  • Clinical aspects of PPAR and RXR agonists in adverse drug reactions
  • Pharmacogenomics of PPARs in the human population with regard to the regulation of drug-metabolizing enzymes in adverse drug reaction and gender-specific role in personalized medicine

Authors should follow the PPAR Research manuscript format described at http://www.hindawi.com/journals/ppar/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore7.100
Impact Factor2.953
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.